Cornea

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

At NOA 2023 in Fort Lauderdale, Florida, Rhea Magee, OD, presented a pediatric patient case as part of the Resident Grand Rounds.

Keratopigmentation technique offers therapeutic and cosmetic applications.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

Jacqueline Theis, OD, FAAO, shares insights from her AOA 2023 presentation on treating neurologic dry eye.

Melissa Barnett, OD, FAAO, FSLS, FBCLA, shares insights from her AOA 2023 presentation on managing keratoconus in clinical practice.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.

Surgical interventions once disease progresses.

The evolution opens doors for the treatment of neurotrophic keratitis and beyond.

Speaking at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Marcony Santhiago, MD, points out there are subtle differences in patients with keratoconus that was progressing compared with patients whose disease was stable and healthy control subjects.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

Uri Soiberman, MD, shares some key takeaways from his presentation at the inaugural IKA Keratoconus Symposium.

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression, strabismus surgery, and eyelid recession.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

An important take-away was the total and central corneal staining score improving after only 2 weeks of treatment.

Based on the initial ophthalmic findings, it is difficult but important to predict the patients’ progression to a specific level of disease severity.

Cochair Elizabeth Yeu, MD, highlights what this program will mean for ophthalmologists, optometrists, and their patients.

The primary outcome was an association between alcohol misuse and corneal endothelial metrics.